The non-erythroid myeloblast count rule in myelodysplastic syndromes: fruitful or futile?

Haematologica. 2019 Dec;104(12):e547-e550. doi: 10.3324/haematol.2018.212563. Epub 2019 Apr 19.

Authors

Margot F van Spronsen¹, Theresia M Westers¹, Birgit I Lissenberg-Witte², Mariëlle Wondergem¹, Gert J Ossenkoppele¹, Arjan A van de Loosdrecht³

Affiliations

¹ Department of Hematology, Amsterdam UMC, location Vrije Universiteit Amsterdam, Cancer Center Amsterdam.
² Department of Epidemiology and Biostatistics, Amsterdam UMC, location Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
³ Department of Hematology, Amsterdam UMC, location Vrije Universiteit Amsterdam, Cancer Center Amsterdam [email protected].

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bone Marrow Cells / pathology*
Combined Modality Therapy
Erythroid Cells / pathology*
Follow-Up Studies
Granulocyte Precursor Cells / pathology*
Humans
Myelodysplastic Syndromes / mortality*
Myelodysplastic Syndromes / pathology*
Myelodysplastic Syndromes / therapy
Prognosis
Retrospective Studies
Stem Cell Transplantation / mortality
Survival Rate